2023 Category Watch: A closer look at disruption

TELUS Health’s 2023 Category Watch closely examines disruption in the drug categories of diabetes, attention deficit hyperactivity disorder (ADHD) and cystic fibrosis.

Without exception, utilization trends in these categories are evidence of transformative change. The handful of drugs driving such change represent advancements in treatment that can significantly improve quality of life—including productivity in the workplace.

These drugs have also had a significant impact on drug spend by private drug plans. The total eligible amount for these three drug categories more than doubled in five years, surpassing $1.1 billion in TELUS Health’s book of business in 2022.

Download your copy of the TELUS Health 2023 Category Watch, with expert analyses from Vicky Lee, Manager, Pharmacy Consulting.